Abstract:Local control rates after SCRT (50 Gy) are very poor in advanced esophageal cancer. Most local failures (LF) occur in the GTV. HFRT allows for delivering a higher total dose without increasing late toxicity. We hypothesized that the use of HFRT boost to the GTV after SCRT using modern image-guided intensity-modulated radiation therapy (IG-IMRT) could potentially intensify local therapy and subsequently improve outcomes. The primary objective of this phase I trial was to define the maximum tolerated dose (MTD) of the HFRT boost with concurrent weekly C/P following SCRT. Patients (pts) who were inoperable or medically unresectable and metastatic with life expectancy ≥ 4 months were eligible. The lower thoracic esophageal cancer involving the stomach was ineligible. Pts were treated with weekly P at 45 mg/m2 and C area under the curve 1.5 with concurrent 50 Gy of IG-IMRT given in 25 fractions for 5 weeks, immediately followed by an image-guided intensity-modulated HFRT boost to the GTV concurrent with the same chemotherapy regimen. The boost doses were escalated ranging from 7.2 to 43.2 Gy in increments of 7.2 Gy delivered in 6 twice daily fractions of 1.2 Gy using a modified Fibonacci design. A minimum of 6 weeks follow-up was required after completion of radiation treatment before proceeding to the next dose. Dose limiting toxicity (DLT) was defined as grade ≥ 4 esophagitis or any other grade ≥ 3 non-hematological toxicity (except nausea and vomiting) or grade ≥ 4 hematological toxicity lasting more than 7 days, which are possibly, probably or definitely associated with protocol treatment occurring during and after completion of the HFRT boost treatment. The MTD was defined as the highest radiation dose at which ≤ 1 pts experienced DLT. Once the MTD was determined, this cohort was expanded to further define the safety profile. Adjuvant chemotherapy was optional. Thirty-four pts were enrolled and 31 were assessable (median age, 62 years; 73% male; 97% T3-4 disease, 65% N1-2 disease; 9% M1 disease; 97% squamous cell carcinoma; 90% PS 0-1).SCRT was well tolerated. The incidence of DLT was 0/3, 0/3, 0/3, 1/6 (grade 4 esophagitis), 0/3, 2/3 (grade 5 esophageal fistula and grade 3 pneumotitis each) at 7.2, 14.4, 21.6, 28.8, 36, and 43.2 Gy, respectively, thus defining the MTD at 36 Gy. In the expansion cohort of 10 pts at the MTD, no DLTs were encountered. The most common acute grade 3 or greater toxicities throughout the entire study period were esophagitis (26%) and neutropenia (19%). Late toxicity included grade 2 esophageal stricture (n = 4). The overall response rate was 84% (95% CI, 42% to 93%; 100% at a dose of ≥ the MTD). With a median follow up of 5 months (range 1 to 12 months), no LF was observed, and distant failure occurred in 3 pts. The MTD of a HFRT boost was determined to be 36 Gy using IG-IMRT with concurrent P and C following 50 Gy of SCRT, resulting in the total combined tumor dose of 86 Gy. Preliminary efficacy data are encouraging. A Phase II study to further evaluate this regimen is underway.

A phase Ⅰ study of concurrent S-1 and IMRT as adjuvant treatment for locally advanced gastric cancer after operation

Effect of Intensity Modulated Radiotherapy Combined with S-1-based Chemotherapy in Locally Advanced Gastric Cancer Patients.

Phase I Study of Postoperative Radiotherapy Concurrent with S-1 in Patients with Gastric Cancer

Efficacy of S-1 and concurrent intensity-modulated radiotherapy for locally advanced gastric cancer:an interim study of phase Ⅱ clinical trial

Efficacy of S-1 and concurrent intensity-modulated radiotherapy for locally advanced gastric cancer: an interim study of phase II clinical trial

S-1 Chemotherapy and Intensity-Modulated Radiotherapy after D1/D2 Lymph Node Dissection in Patients with Node-Positive Gastric Cancer: a Phase I/II Study.

Phase I Study of Dose-Escalated Intensity-Modulated Hyperfractionated Radiation Therapy (HFRT) Boost with Concurrent Paclitaxel (P) and Carboplatin (C) to Gross Tumor Volume (GTV) Following Standard-Dose Chemoradiotherapy (SCRT) for Advanced Esophageal Ca

A Phase Iii Study of S-1 Plus Cisplatin Versus Fluorouracil Plus Cisplatin in Patients with Advanced Gastric or Gastroesophageal Junction Adenocarcinoma

Clinical Study of Compound Tegafur and Oteracil Potassium Sustained Capsules (S-1) in the Treatment of Advanced Gastric Cancer

Phase Ⅰ Trial of Postoperative Concurrent Capecitabine and Intensity-Modulated Radiotherapy for Locally Advanced Gastric Cancer

S-1 plus cisplatin versus fluorouracil plus cisplatin in advanced gastric or gastro-esophageal junction adenocarcinoma patients: a pilot study

Phase Ⅱ trial of low dosage S-1 concurrent with radiotherapy in patients with locally advanced or recurrent pancreatic cancer

Dose-finding study on adjuvant chemotherapy with S-1 plus oxaliplatin for gastric cancer.

Phase I study of neoadjuvant chemoradiotherapy with S-1 for clinically resectable type 4 or large type 3 gastric cancer in elderly patients aged 75 years and older (OGSG1303)

Phase I Study of Postoperative Radiotherapy Combined with Capecitabine for Gastric Cancer

A Phase Ii Study of Biweekly Oxaliplatin and S-1(Sox) As First-Line Combination Therapy in Patients with Advanced Gastric Cancer.

A single centre clinical trial of docetaxel and S-1 combination therapy as first line treatment in patients with advanced or recurrent gastric cancer

A Phase I Dose Escalation Study of S-1 with Concurrent Radiotherapy in Elderly Patients with Esophageal Cancer.

Interim assessment of prospective phase Ⅱ trial evaluating efficacy of intensity-modulated radiotherapy with concurrent capecitabine for stage Ⅱ / Ⅲ gastric cancer after radical surgery

A phase II study of S-1 with concurrent radiotherapy in elderly patients with esophageal cancer.

Adjuvant treatment with S-1 in patients after R0-resection of adenocarcinoma of the stomach and esophagogastric junction – A multicenter phase I/II feasibility study (GMBH-STO-0114)